ISPOR - EE304 A Cost Minimization and Budget Impact Analysis of an Eculizumab Biosimilar, ABP 959, From the Spanish Healthcare Perspective

Full Text

EE304 A Cost Minimization and Budget Impact Analysis of an Eculizumab Biosimilar, ABP 959, From the Spanish Healthcare Perspective

Abstract

Authors

Fiston Vuvu Joshua Porter Marta Sacrest Matthew Arden Alex Hirst Seun Lashilola

Back to Volume 28, Supplemental Issue 6S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now